SBShuken Boku

Shuken Boku

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuken Boku has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Akitoyo Hishimoto

    Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan; Department of Psychiatry, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    3 shared publications
  • Ikuo Otsuka

    Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan

    2 shared publications
  • Satoshi Okazaki

    Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan

    2 shared publications
  • Ai Koizumi

    Sony Computer Science Laboratories, Inc., Tokyo, Japan

    1 shared publication
  • Akira Monji

    Department of Psychiatry, Saga University Faculty of Medicine, Saga, Japan

    1 shared publication
  • Akitoyo Hishimoto

    Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan

    1 shared publication

Latest Publications

  • miR-19b is elevated in peripheral blood of schizophrenic patients and attenuates proliferation of hippocampal neural progenitor cells

    by Tadasu Horai, Shuken Boku, Satoshi Okazaki, Ikuo Otsuka, Woraphat Ratta-Apha, Kentaro Mouri, Naruhisa Yamaki, Takashi Hirata, Akitoyo Hishimoto


  • ATP and repetitive electric stimulation increases leukemia inhibitory factor expression in astrocytes: A potential role for astrocytes in the action mechanism of electroconvulsive therapy

    by Soichiro Maruyama, Shuken Boku, Satoshi Okazaki, Hiroki Kikuyama, Yoshito Mizoguchi, Akira Monji, Ikuo Otsuka, Ichiro Sora, Tetsufumi Kanazawa, Akitoyo Hishimoto, et al.

    Aim: Electroconvulsive therapy (ECT) is effective for psychiatric disorders. However, its action mechanism remains unclear. We previously reported that transcription factor 7 (TCF7) was increased in patients successfully treated with ECT. TCF7 regulates Wnt pathway, which regulates adult hippocampal neurogenesis. Adult hippocampal neurogenesis is involved in the pathophysiology of psychiatric disorders. Astrocytes play a role in adult hippocampal neurogenesis via neurogenic factors. Of astrocyte‐derived neurogenic factors, leukemia inhibitory factor (LIF) and fibroblast growth factor 2 (FGF2) activate Wnt pathway. In addition, adenosine triphosphate (ATP), released from excited neurons, activates astrocytes. Therefore, we hypothesized that ECT might increase LIF and/or FGF2 in astrocytes. To test this, we investigated the effects of ATP and electric stimulation (ES) on LIF and FGF2 expressions in astrocytes.Methods: Astrocytes were derived from neonatal mouse forebrain and administered ATP and ES. The mRNA expression was estimated with quantitative reverse‐transcription polymerase chain reaction. Protein concentration was measured with ELISA.Results: ATP increased LIF, but not FGF2, expression. Multiple ES, but not single, increased LIF expression. Knockdown of P2X2 receptor (P2X2R) attenuated ATP‐induced increase of LIF mRNA expression. In contrast, P2X3 and P2X4 receptors intensified it.Conclusion: P2X2R may mediate ATP‐induced LIF expression in astrocytes and multiple ES directly increases LIF expression in astrocytes. Therefore, both ATP/P2X2R and multiple ES‐induced increases of LIF expression in astrocytes might mediate the efficacy of ECT on psychiatric disorders. Elucidating detailed mechanisms of ATP/P2X2R and multiple ES‐induced LIF expression is expected to result in the identification of new therapeutic targets for psychiatric disorders.


  • Open Access

    A reciprocal inhibition model of alternations between non-dissociative and dissociative states in patients with PTSD

    by Toshinori Chiba, Kentaro Ide, Shuken Boku, Jessica E. Taylor, Hiroyuki Toda, Tetsufumi Kanazawa, Sumie Kato, Yuka Horiuchi, Akitoyo Hishimoto, Toru Maruyama, et al.

    Objective: Traumatic life-events can leave individuals with contrasting posttraumatic stress disorder (PTSD) symptoms, including re-experiencing and avoidance. Notably, patients with PTSD are known to periodically switch between two opposing attentional biases; namely, toward threat and away from threat. We hypothesized that reciprocal inhibition between the amygdala and ventromedial prefrontal cortex (vmPFC) may induce alternations between these attentional biases, which in turn may contribute to the re-experiencing and avoidance symptoms, respectively. Methods: To test this reciprocal inhibition model, we performed an experiment to measure the attentional biases of patients with PTSD. We examined the differential relationships between PTSD symptom clusters (re-experiencing/avoidance) and attentional biases (toward/away from threat). Additionally, we performed a meta-regression analysis to examine the role of amygdala reactivity in the imbalance between re-experiencing and avoidance symptoms. Results: We found that attentional bias toward threat was selectively associated with re-experiencing symptoms whereas attentional bias away from threat was selectively associated with avoidance symptoms. Meta-regression analysis based on twelve participant populations (total N = 316) revealed that left amygdala activity was positively correlated with the severity of re-experiencing symptoms relative to avoidance symptoms. Conclusions: Our findings support the hypothesis that reciprocal inhibition of common neural circuits may underlie the switch between attentional biases toward and away from threat as well as that between re-experiencing and avoidance symptoms. Re-experiencing and avoidance/emotional numbing are the core symptoms used to distinguish between the non-dissociative and dissociative PTSD subtypes. The reciprocal inhibition mechanism may help elucidate the mechanisms underlying those PTSD subtypes.

  • Top Cited Papers

    Neural basis of major depressive disorder: Beyond monoamine hypothesis

    by Shuken Boku, Shin Nakagawa, Hiroyuki Toda, Akitoyo Hishimoto

    The monoamine hypothesis has been accepted as the most common hypothesis of major depressive disorder (MDD) for a long period because of its simplicity and understandability. Actually, most currently used antidepressants have been considered to act based on the monoamine hypothesis. However, an important problem of the monoamine hypothesis has been pointed out as follows: it fails to explain the latency of response to antidepressants. In addition, many patients with MDD have remained refractory to currently used antidepressants. Therefore, monoamine‐alternate hypotheses are required to explain the latency of response to antidepressants. Such hypotheses have been expected to contribute to identifying hopeful new therapeutic targets for MDD. Past studies have revealed that the volume of the hippocampus is decreased in patients with MDD, which is likely caused by the failure of the hypothalamic–pituitary–adrenal axis and following elevation of glucocorticoids. Two hypotheses have been proposed to explain the volume of the hippocampus: (i) the neuroplasticity hypothesis; and (ii) the neurogenesis hypothesis. The neuroplasticity hypothesis explains how the hippocampal volume is decreased by the morphological changes of hippocampal neurons, such as the shortening length of dendrites and the decreased number and density of spines. The neurogenesis hypothesis explains how the hippocampal volume is decreased by the decrease of neurogenesis in the hippocampal dentate gyrus. These hypotheses are able to explain the latency of response to antidepressants. In this review, we first overview how the neuroplasticity and neurogenesis hypotheses have been developed. We then describe the details of these hypotheses.